1Horwitz KB,Tung L,Takimoto GS.Novel mechanisms of antiprogestin action[J].Acta Oncol,1996,35:129.
2Petrangeli E,Lubrano C,Ortolani F.ER new perspectives in breast cancer management.J Steroid[J].Biochem Mol Biol,1994,49:327.
3Charpin C,Garcia S,Bonnier P,et al.Prognostic significance of nm 23/NDPK expression in breast carcionma,assessed on 10-year follow-up by automated and quantitative immunocytochemical assays[J].J Pathol,1998,184(4):401-407.
4Yoshida H,Kijima H,Terasaki Y,et al.Heterogenous expression of nm 23 gene product as a preditor of lymph nodal satua in human breast cancer[J].Int J Oncol,1998,13(6):1141-1146.
5Sawan A,Lascu I,Veron M,et al.NDPK/nm 23 expression in human breast cancer in relation to telapse,survival and other prognostic fctors:An immunohistochemical study[J].J Pathol,1994,172:127.
6Narita M,Nakao K,Dgino N,et al.Independent prognostic factors in breast cancer patients[J].Am J Surg,1998,175(1):73-75.
7Makris A,Powles TJ,Kakolyris S,et al.Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma[J].Cancer,1999,85(9):1996-2000
8Placido SD,Carlomagno C,Laurentiis MD,et al.c-erbB-2 expression predicts tamoxifen efficacy in breast cancer patients[J].Breast Cancer Res Treat,1998,52(1):55-64.
9Weinstein EJ,Kitsberg DI,Leder P.A mouse model for breast cancer induced by amplification and overexpression of the neu promotor and transgene[J].Mol Med,2000,6(1):4-16.
10Ceccarelli C,Santini D,Gamberini M,et al.Immunohistochemical expression of internal and external ErbB-2 domains in invasive breast cancer[J].Breast Cancer Res Treat,1999,58:107-114.
